Ascentage Pharma releases latest results from multiple clinical studies of lead drug candidates
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Additional data from APPRAISE ATP trial reinforce modular therapy approach
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Subscribe To Our Newsletter & Stay Updated